AstraZeneca PLC or Jazz Pharmaceuticals plc: Who Invests More in Innovation?

AstraZeneca's R&D spending dwarfs Jazz Pharmaceuticals by 13 times in 2023.

__timestampAstraZeneca PLCJazz Pharmaceuticals plc
Wednesday, January 1, 2014557900000085181000
Thursday, January 1, 20155997000000135253000
Friday, January 1, 20165890000000162297000
Sunday, January 1, 20175757000000198442000
Monday, January 1, 20185932000000226616000
Tuesday, January 1, 20195958000000299726000
Wednesday, January 1, 20205991000000335375000
Friday, January 1, 20219736000000505748000
Saturday, January 1, 20229762000000590453000
Sunday, January 1, 202310935000000849658000
Monday, January 1, 202413583000000
Loading chart...

Igniting the spark of knowledge

Innovation Investment: AstraZeneca vs. Jazz Pharmaceuticals

In the competitive world of pharmaceuticals, innovation is key to staying ahead. AstraZeneca PLC and Jazz Pharmaceuticals plc are two giants in the industry, each with a unique approach to research and development (R&D). Over the past decade, AstraZeneca has consistently outpaced Jazz Pharmaceuticals in R&D spending. In 2023, AstraZeneca's investment in innovation was nearly 13 times that of Jazz Pharmaceuticals, highlighting its commitment to pioneering new treatments.

From 2014 to 2023, AstraZeneca's R&D expenses grew by approximately 96%, reflecting a strategic focus on expanding its research capabilities. In contrast, Jazz Pharmaceuticals saw a more modest increase of around 900% in the same period, indicating a more conservative approach. This disparity underscores AstraZeneca's aggressive strategy to lead in pharmaceutical innovation, while Jazz Pharmaceuticals maintains a steady, albeit smaller, investment in its R&D efforts.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025